Previous close | 19.27 |
Open | 19.27 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 19.27 - 19.27 |
52-week range | 11.13 - 20.95 |
Volume | |
Avg. volume | 201 |
Market cap | 561.911M |
Beta (5Y monthly) | 0.77 |
PE ratio (TTM) | 120.47 |
EPS (TTM) | 0.16 |
Earnings date | N/A |
Forward dividend & yield | 0.20 (1.07%) |
Ex-dividend date | 29 Jun 2022 |
1y target est | N/A |
IBA SA – Regulated information January 25th, 2023 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007 ) (hereinafter, the “Law”) Under this provision: "[...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by category, the number of
Louvain-La-Neuve, Belgium, 10 January 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces that it has received the downpayment for a contract signed at the end of December 2022 with the H. Lee Moffitt Cancer Center and Research Institute Hospital (“Moffitt”) in Tampa, Florida, US, for the installation of its Proteus®ONE1 compact proton therapy system. As Florida’s only National Cancer Institute-designated comprehensive cancer ce
Significant contract win for IBA’s Industrial Solutions; first time the division has sold a complete irradiation solution Louvain-La-Neuve, Belgium, 22 December 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announced that it has signed a contract to install a fully integrated X-ray irradiation solution at a customer’s new service center site in France. The solution includes an IBA Rhodotron®, a Beagle® process control system, a safe